|Day Low/High||173.56 / 176.19|
|52 Wk Low/High||150.37 / 236.62|
Cannabis and tobacco are hard to equate, which Barclays' primer on the Cannabis industry misses.
Constellation Brands is the kind of company that typically does well in a weak market environment.
Canopy Growth already has a $4 billion war chest thanks to Constellation Brands.
On Wednesday, Canada becomes the first major economy to legalize the recreational use of cannabis.
But don't buy into this overheated market right as Canada legalizes, wait until prices come down -- which they will.
The Fed's crystal ball is very clouded.
The time to scoop up Altria is now, not when some type of official announcement is made.
These stocks offer some diversification or unique features in the legal-weed space.
Canopy Growth could be Constellation's next big growth engine.
Shareholders enjoyed a crisp day of gains after Constellation cracked open a great earnings report pre-market.
Investors and experts need more time before they go all in on cannabis.
Market experts are abuzz over Constellation's potential new inroads into the cannabis market.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
I have no problem blessing an investment in this name with the appropriate steps taken toward risk management.
A strong upside gap this morning really changes the picture.
Constellation looks to wine, beer, and cannabis to take it higher.
There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.
Constellation looks like a star today after beating expectations.
Try these trades in JPM and Key to take advantage of weakness in the sector.
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
Covered calls may be the best bet -- or wait for a dip.
This options trade combines some upside with a chance to buy TLRY at a decent price.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.